Entera Bio Ltd. (NASDAQ: ENTX) shares rebounded Wednesday after the company announced an oversubscribed private placement expected to raise approximately $275 million. The capital injection is designed to fully fund Phase 3 registrational studies for EB613, its lead oral PTH(1-34) peptide tablet for osteoporosis, and extend the company’s cash runway into 2030. Investors weighed the significant liquidity boost against dilution concerns from the large securities issuance, driving the stock higher despite broader market headwinds.

The financing involves the sale of approximately 122.96 million ordinary shares and pre-funded warrants covering up to 11.84 million shares. Entera priced the ordinary shares at $2.04 each, with warrants priced at $2.04 minus their nominal exercise price. The gross proceeds of $275 million are stated before the deduction of placement agent fees and other offering expenses.

Investor Participation and Governance

Existing investor BVF Partners L.P. led the financing, alongside Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Driehaus Capital Management, Logos Capital, Catalio Capital Management, and other investors. Following the closing, BVF will gain the right to designate two directors to Entera’s board, subject to applicable requirements.

Market Reaction and Technical Outlook

Entera Bio stock traded at elevated levels, reaching $3.20, significantly above its 20-day simple moving average (SMA) of $2.07. The Relative Strength Index (RSI) hit 70.83, signaling overbought conditions. Key resistance sits at $4.20, the 52-week high, while support aligns with the 20-day SMA at $2.07. At the time of publication, shares were up 0.31% at $3.27.

Financial Outlook

Analysts project Entera Bio will report a loss of eight cents per share when earnings are released on Aug. 11, wider than the six cents loss previously reported, with no revenue expected. HC Wainwright maintains a Buy rating with a price target of $9.

What the Numbers Show

The oversubscribed nature of the $275 million raise indicates strong institutional confidence in EB613’s commercial potential. By securing funds through 2030, Entera mitigates near-term dilution risks associated with frequent fundraising, allowing management to focus on clinical execution for its lead asset.

Entera Bio Ltd. (NASDAQ: ENTX) has secured positive feedback from the U.S. Food and Drug Administration (FDA) for its Phase 3 registrational protocol for EB613 (oral PTH(1-34), teriparatide), the first oral anabolic tablet in development for the treatment of osteoporosis. The agency accepted the company's plan to conduct a single, randomized, double-blind, placebo-controlled trial in approximately 750 postmenopausal women with osteoporosis. This regulatory alignment follows a Clinical Amendment submitted by Entera to its Investigational New Drug (IND) application in March 2026 and positions the company to advance what could become the first oral anabolic treatment for osteoporosis.

The primary endpoint of the study is the percent change from baseline in total hip bone mineral density (BMD) at Month 12. This data is intended to support a potential New Drug Application (NDA) submission for EB613 for the treatment of women with post-menopausal osteoporosis. The proposed NDA package will include a scientific bridge analysis with Forteo (teriparatide SC injection, Eli Lilly) under the 505(b)(2) pathway and a transiliac crest bone biopsy sub-study in a subset of patients. The FDA's decision builds on its December 2025 qualification of total hip BMD as a validated surrogate endpoint for osteoporosis drug development.

Study Design and Timeline

The FDA agreed to Entera's proposal to follow randomized patients for 24 months in an open-label extension study under a separate protocol. Entera plans to submit data through up to 18 months as part of a 120-day safety update to its NDA. The complete 2-year data will be submitted upon completion of the extension study to characterize the durability of the treatment effect, safety, and sequence data for EB613 followed by a standard anti-resorptive therapy.

Clinical Effectiveness and Market Context

The registrational study is powered to demonstrate EB613's clinical effectiveness with projected increases in total hip BMD comparable to reported outcomes for Forteo at 12 months. These changes are associated with a 60% to 80% relative reduction in vertebral fracture risk. Entera previously completed a 6-month Phase 2 study of EB613 in 161 postmenopausal women, which met its primary and secondary endpoints with statistically significant increases in BMD at the lumbar spine, total hip, and femoral neck.

The market opportunity for EB613 is substantial, as osteoporosis affects an estimated 200 million women worldwide and is responsible for more than two million fractures each year in the United States alone. Forteo, the injectable version of teriparatide, achieved peak annual sales of approximately $1.7 billion prior to patent expiration. Entera Bio aims to democratize anabolic treatment by converting this injectable therapy into a simple daily tablet, potentially addressing the low real-world adoption caused by injection requirements.

Pipeline and Platform Potential

While EB613 remains the lead asset, Entera Bio is advancing a broader pipeline of oral peptide programs using its proprietary N-Tab platform. The company is developing EB612, an oral long-acting PTH tablet for hypoparathyroidism, and EB618, an oral GLP-1/glucagon peptide tablet for obesity and metabolic disease, in collaboration with OPKO Health. Recent data presented at ENDO 2026 highlighted the single-tablet version of EB613, showing a pharmacokinetic and pharmacodynamic profile comparable to both injectable Forteo and the multi-tablet version of EB613.

Miranda Toledano, Chief Executive Officer of Entera, stated that the company has a clear and optimized registrational path to get EB613 to women with osteoporosis. She emphasized the goal of democratizing anabolic treatment to enable millions of women and men to protect their bones and potentially prevent fractures.